Quest Diagnostics Reports Fourth Quarter And Full Year 2018 Financial Results; Provides Guidance For Full Year 2019
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Quest Diagnostics (DGX) PT Lowered to $100 at Baird
February 15, 2019 10:15 AM ESTBaird analyst Eric Coldwell lowered the price target on Quest Diagnostics (NYSE: DGX) to $100.00 (from $106.00) while maintaining a Outperform rating following the company's 4Q. Revenue missed the lowered November IR day target by ~$40M. $35M of downside due to additional reserve for payer denials,... More
Quest Diagnostics (DGX) Misses Q4 EPS by 3c, Revenues; Offers FY19 EPS/Revenue Guidance Below Consensus
February 14, 2019 6:50 AM ESTQuest Diagnostics (NYSE: DGX) reported Q4 EPS of $1.36, $0.03 worse than the analyst estimate of $1.39. Revenue for the quarter came in at $1.84 billion versus the consensus estimate of $1.88 billion.
"In 2018 we grew revenues, adjusted earnings and cash from operations despite some challenges in the... More
